In	O
primary	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
we	O
show	O
that	O
CD28	B-protein
ligation	O
leads	O
to	O
the	O
rapid	O
intracellular	O
formation	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROIs	O
)	O
which	O
are	O
required	O
for	O
CD28	B-protein
-mediated	O
activation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
/	O
CD28-responsive	B-protein
complex	I-protein
and	O
IL-2	B-protein
expression	O
.	O


These	O
findings	O
should	O
be	O
useful	O
for	O
therapeutic	O
strategies	O
and	O
the	O
development	O
of	O
immunosuppressants	O
targeting	O
the	O
CD28	B-protein
costimulatory	O
pathway	O
.	O


Consistent	O
with	O
these	O
differences	O
,	O
we	O
have	O
previously	O
demonstrated	O
that	O
the	O
enhancer/promoter	B-DNA
region	I-DNA
of	O
HIV-2	O
functions	O
quite	O
differently	O
from	O
that	O
of	O
HIV-1	O
.	O


Whereas	O
activation	O
of	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
following	O
T-cell	O
stimulation	O
is	O
mediated	O
largely	O
through	O
binding	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
to	O
two	O
adjacent	O
kappa	B-DNA
B	I-DNA
sites	I-DNA
in	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
,	O
activation	O
of	O
the	O
HIV-2	B-DNA
enhancer	I-DNA
in	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
is	O
dependent	O
on	O
four	O
cis-acting	B-DNA
elements	I-DNA
:	O
a	O
single	O
kappa	B-DNA
B	I-DNA
site	I-DNA
,	O
two	O
purine-rich	B-DNA
binding	I-DNA
sites	I-DNA
,	O
PuB1	B-DNA
and	O
PuB2	B-DNA
,	O
and	O
a	O
pets	B-DNA
site	I-DNA
.	O


This	O
is	O
the	O
first	O
description	O
of	O
an	O
HIV-2	B-DNA
enhancer	I-DNA
element	I-DNA
which	O
displays	O
such	O
monocyte	O
specificity	O
,	O
and	O
no	O
comparable	O
enhancer	B-DNA
element	I-DNA
has	O
been	O
clearly	O
defined	O
for	O
HIV-1	O
.	O


E1A	B-DNA
gene	I-DNA
expression	O
induces	O
susceptibility	O
to	O
killing	O
by	O
NK	B-cell_type
cells	I-cell_type
following	O
immortalization	O
but	O
not	O
adenovirus	O
infection	O
of	O
human	B-cell_type
cells	I-cell_type
.	O


Adenovirus	O
(	O
Ad	O
)	O
infection	O
and	O
E1A	B-protein
transfection	O
were	O
used	O
to	O
model	O
changes	O
in	O
susceptibility	O
to	O
NK	O
cell	O
killing	O
caused	O
by	O
transient	O
vs	O
stable	O
E1A	B-protein
expression	O
in	O
human	B-cell_type
cells	I-cell_type
.	O


The	O
inability	O
of	O
E1A	B-DNA
gene	I-DNA
products	O
to	O
induce	O
cytolytic	O
susceptibility	O
during	O
infection	O
was	O
not	O
explained	O
by	O
an	O
inhibitory	O
effect	O
of	O
viral	O
infection	O
on	O
otherwise	O
susceptible	O
target	B-cell_type
cells	I-cell_type
or	O
by	O
viral	B-DNA
gene	I-DNA
effects	O
on	O
class	B-protein
I	I-protein
MHC	I-protein
antigen	I-protein
expression	O
on	O
target	B-cell_type
cells	I-cell_type
.	O


We	O
have	O
investigated	O
the	O
effect	O
of	O
CD4	B-protein
triggering	O
on	O
T	O
cell	O
activating	O
signals	O
in	O
a	O
lymphoma	O
model	O
using	O
monoclonal	B-protein
antibodies	I-protein
(	O
mAb	B-protein
)	O
which	O
recognize	O
different	O
CD4	B-protein
epitopes	I-protein
.	O


Whereas	O
different	O
anti-CD4	B-protein
mAb	I-protein
or	O
HIV-1	B-protein
gp120	I-protein
could	O
all	O
trigger	O
activation	O
of	O
the	O
protein	B-protein
tyrosine	I-protein
kinases	I-protein
p56lck	B-protein
and	O
p59fyn	B-protein
and	O
phosphorylation	O
of	O
the	O
Shc	B-protein
adaptor	I-protein
protein	I-protein
,	O
which	O
mediates	O
signals	O
to	O
Ras	B-protein
,	O
they	O
differed	O
significantly	O
in	O
their	O
ability	O
to	O
activate	O
NF-AT	B-protein
.	O


The	O
results	O
identify	O
functionally	O
distinct	O
epitopes	B-protein
on	O
the	O
CD4	B-protein
coreceptor	I-protein
involved	O
in	O
activation	O
of	O
the	O
Ras/protein	B-protein
kinase	I-protein
C	I-protein
and	O
calcium	O
pathways	O
.	O


In	O
chickens	O
,	O
estrogens	O
stimulate	O
outgrowth	O
of	O
bone	B-cell_type
marrow-derived	I-cell_type
erythroid	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
and	O
delay	O
their	O
maturation	O
.	O


We	O
show	O
here	O
that	O
estrogens	O
also	O
reduce	O
the	O
number	O
of	O
erythroid	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
in	O
primary	B-cell_line
human	I-cell_line
bone	I-cell_line
marrow	I-cell_line
cultures	I-cell_line
.	O


We	O
demonstrate	O
that	O
the	O
transcriptional	O
activity	O
of	O
GATA-1	B-protein
is	O
strongly	O
repressed	O
by	O
the	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
in	O
a	O
ligand-dependent	O
manner	O
and	O
that	O
this	O
repression	O
is	O
reversible	O
in	O
the	O
presence	O
of	O
4-hydroxytamoxifen	O
.	O


In	O
coimmunoprecipitation	O
experiments	O
using	O
transfected	O
COS	B-cell_line
cells	I-cell_line
,	O
GATA-1	B-protein
and	O
ER	B-protein
associate	O
in	O
a	O
ligand-dependent	O
manner	O
.	O


We	O
speculate	O
that	O
estrogens	O
exert	O
effects	O
on	O
erythropoiesis	O
by	O
modulating	O
GATA-1	B-protein
activity	O
through	O
protein-protein	O
interaction	O
with	O
the	O
ER	B-protein
.	O


Interleukin-1	B-protein
and	O
interleukin-2	B-protein
control	O
transcription	O
via	O
distinct	O
cis-acting	B-DNA
elements	I-DNA
.	O


Here	O
we	O
map	O
the	O
cis-acting	B-DNA
elements	I-DNA
that	O
mediate	O
interleukin	O
responsiveness	O
of	O
the	O
mouse	B-DNA
IL-2R	I-DNA
alpha	I-DNA
gene	I-DNA
using	O
a	O
thymic	B-cell_line
lymphoma-derived	I-cell_line
hybridoma	I-cell_line
(	O
PC60	B-cell_line
)	O
.	O


It	O
also	O
primes	O
cells	O
to	O
become	O
IL-2	B-protein
responsive	O
and	O
thereby	O
prepares	O
the	O
second	O
phase	O
,	O
in	O
which	O
IL-2	B-protein
induces	O
a	O
100-fold	O
further	O
increase	O
in	O
IL-2R	B-RNA
alpha	I-RNA
transcripts	I-RNA
.	O


Transient	O
transfection	O
experiments	O
show	O
that	O
several	O
elements	O
in	O
the	O
promoter-proximal	B-DNA
region	I-DNA
of	O
the	O
IL-2R	B-DNA
alpha	I-DNA
gene	I-DNA
contribute	O
to	O
IL-1	B-protein
responsiveness	O
,	O
most	O
importantly	O
an	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
conserved	O
in	O
the	O
human	B-DNA
and	I-DNA
mouse	I-DNA
gene	I-DNA
.	O


This	O
segment	O
functions	O
as	O
an	O
IL-2-inducible	B-DNA
enhancer	I-DNA
and	O
lies	O
within	O
a	O
region	O
that	O
becomes	O
DNase	B-protein
I	I-protein
hypersensitive	O
in	O
normal	O
T	B-cell_type
cells	I-cell_type
in	O
which	O
IL-2R	B-protein
alpha	I-protein
expression	O
has	O
been	O
induced	O
.	O


Hematopoietic	B-cell_type
lineage	I-cell_type
commitment	O
:	O
role	O
of	O
transcription	B-protein
factors	I-protein
.	O


This	O
review	O
focuses	O
on	O
the	O
roles	O
of	O
transcription	B-protein
factors	I-protein
in	O
hematopoietic	O
lineage	O
commitment	O
.	O


Next	O
is	O
presented	O
a	O
discussion	O
of	O
the	O
use	O
of	O
embryonic	B-cell_type
stem	I-cell_type
cells	I-cell_type
in	O
the	O
analysis	O
of	O
hematopoietic	B-DNA
gene	I-DNA
expression	O
and	O
the	O
use	O
of	O
targeted	O
gene	O
disruption	O
to	O
analyze	O
the	O
role	O
of	O
transcription	B-protein
factors	I-protein
in	O
hematopoiesis	O
.	O


Epstein-Barr	O
virus	O
replicative	O
gene	O
transcription	O
during	O
de	O
novo	O
infection	O
of	O
human	B-cell_type
thymocytes	I-cell_type
:	O
simultaneous	O
early	O
expression	O
of	O
BZLF-1	B-protein
and	O
its	O
repressor	O
RAZ	B-protein
.	O


We	O
and	O
others	O
have	O
shown	O
that	O
EBV	O
can	O
also	O
infect	O
a	O
subset	O
of	O
thymocytes	B-cell_type
.	O


Circularization	O
of	O
the	O
EBV	B-DNA
genome	I-DNA
was	O
not	O
detected	O
.	O


Transcripts	O
encoding	O
gp350/220	B-protein
,	O
the	O
major	B-protein
coat	I-protein
protein	I-protein
of	O
EBV	O
,	O
were	O
identified	O
,	O
but	O
we	O
did	O
not	O
find	O
any	O
evidence	O
of	O
transcription	O
from	O
the	O
LMP-2A	B-DNA
or	O
EBER-1	B-DNA
loci	I-DNA
in	O
infected	O
thymocytes	B-cell_type
.	O


These	O
observations	O
suggest	O
that	O
de	O
novo	O
EBV	O
infection	O
of	O
thymocytes	B-cell_type
differs	O
from	O
infection	O
of	O
B	B-cell_type
cells	I-cell_type
.	O


Identification	O
and	O
purification	O
of	O
human	B-protein
Stat	I-protein
proteins	I-protein
activated	O
in	O
response	O
to	O
interleukin-2	B-protein
.	O


Several	O
recent	O
studies	O
have	O
implicated	O
Jak	O
kinases	O
in	O
the	O
signaling	O
pathway	O
induced	O
by	O
IL-2	B-protein
.	O


Human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
were	O
observed	O
to	O
contain	O
several	O
IL-2	B-protein
-inducible	O
DNA	O
binding	O
activities	O
.	O


We	O
hypothesize	O
that	O
activation	O
of	O
this	O
protein	O
,	O
designated	O
hStat5	B-protein
,	O
helps	O
govern	O
the	O
biological	O
effects	O
of	O
IL-2	B-protein
during	O
the	O
immune	O
response	O
.	O


We	O
demonstrate	O
,	O
through	O
the	O
deletion	O
of	O
the	O
human	B-DNA
UDG	I-DNA
promoter	I-DNA
sequences	I-DNA
,	O
that	O
expression	O
of	O
E2F-1	B-protein
activates	O
the	O
UDG	B-DNA
promoter	I-DNA
through	O
several	O
E2F	B-DNA
sites	I-DNA
.	O


We	O
also	O
provide	O
evidence	O
for	O
the	O
functional	O
relationship	O
between	O
the	O
cyclin-like	B-protein
UDG	I-protein
gene	I-protein
product	I-protein
and	O
E2F	B-protein
.	O


High	O
levels	O
of	O
UDG	B-protein
expression	O
in	O
a	O
transient	O
transfection	O
assay	O
result	O
in	O
the	O
down-regulation	O
of	O
transcriptional	O
activity	O
through	O
elements	B-DNA
specific	O
for	O
E2F	B-protein
-mediated	O
transcription	O
.	O


Cellular	O
and	O
molecular	O
mechanisms	O
of	O
IFN-gamma	B-protein
production	O
induced	O
by	O
IL-2	B-protein
and	O
IL-12	B-protein
in	O
a	O
human	B-cell_line
NK	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O


Interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
is	O
an	O
important	O
immunoregulatory	B-protein
protein	I-protein
produced	O
predominantly	O
by	O
T	B-cell_type
cells	I-cell_type
and	O
large	B-cell_type
granular	I-cell_type
lymphocytes	I-cell_type
(	O
LGL	B-cell_type
)	O
in	O
response	O
to	O
different	O
extracellular	O
signals	O
.	O


The	O
results	O
suggest	O
that	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
but	O
not	O
new	O
protein	O
synthesis	O
,	O
is	O
required	O
for	O
IL-2	B-protein
induction	O
of	O
IFN-gamma	B-RNA
and	I-RNA
GM-CSF	I-RNA
cytoplasmic	I-RNA
mRNA	I-RNA
.	O


Furthermore	O
,	O
both	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
and	O
genistein	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
could	O
suppress	O
IL-2	B-protein
and	O
IL-12	B-protein
signaling	O
but	O
CsA	O
was	O
generally	O
inactive	O
.	O


It	O
also	O
was	O
observed	O
that	O
suppression	O
of	O
cytokine	B-DNA
gene	I-DNA
expression	O
by	O
these	O
agents	O
was	O
independent	O
of	O
the	O
inhibition	O
of	O
proliferation	O
.	O


These	O
data	O
indicate	O
that	O
IL-2	B-protein
and	O
IL-12	B-protein
may	O
have	O
distinct	O
signaling	O
pathways	O
leading	O
to	O
the	O
induction	O
of	O
IFN-gamma	B-protein
and	O
GM-CSF	B-protein
gene	O
expression	O
,	O
and	O
that	O
the	O
NK3.3	B-cell_line
cell	I-cell_line
line	I-cell_line
may	O
serve	O
as	O
a	O
novel	O
model	O
for	O
dissecting	O
the	O
biochemical	O
and	O
molecular	O
events	O
involved	O
in	O
these	O
pathways	O
.	O


A	O
functional	O
T-cell	B-protein
receptor	I-protein
signaling	O
pathway	O
is	O
required	O
for	O
p95vav	B-protein
activity	O
.	O


One	O
substrate	O
is	O
p95vav	B-protein
,	O
which	O
is	O
expressed	O
exclusively	O
in	O
hematopoietic	B-cell_type
and	I-cell_type
trophoblast	I-cell_type
cells	I-cell_type
.	O


It	O
contains	O
a	O
number	O
of	O
structural	B-protein
motifs	I-protein
,	O
including	O
Src	B-protein
homology	I-protein
2	I-protein
,	I-protein
Src	I-protein
homology	I-protein
3	I-protein
,	I-protein
and	I-protein
pleckstrin	I-protein
homology	I-protein
domains	I-protein
and	O
a	O
putative	B-protein
guanine	I-protein
nucleotide	I-protein
exchange	I-protein
domain	I-protein
.	O


Furthermore	O
,	O
p95vav	B-protein
synergizes	O
with	O
TCR	B-protein
stimulation	O
in	O
inducing	O
NFAT-	O
and	O
interleukin-2-dependent	O
transcription	O
.	O


Although	O
removal	O
of	O
the	O
first	B-protein
67	I-protein
amino	I-protein
acids	I-protein
of	O
p95vav	B-protein
activates	O
its	O
transforming	O
potential	O
in	O
NIH	B-cell_line
3T3	I-cell_line
cells	I-cell_line
,	O
this	O
region	O
appears	O
to	O
be	O
required	O
for	O
its	O
function	O
in	O
T	B-cell_type
cells	I-cell_type
.	O


We	O
further	O
demonstrate	O
that	O
the	O
p95vav	B-protein
-induced	O
NFAT	B-protein
activation	O
is	O
not	O
mimicked	O
by	O
Ras	B-protein
activation	O
,	O
though	O
its	O
function	O
is	O
dependent	O
upon	O
Ras	B-protein
and	O
Raf	B-protein
.	O


However	O
,	O
overexpression	O
of	O
p95vav	B-protein
does	O
not	O
appear	O
to	O
influence	O
TCR	B-protein
-induced	O
protein	O
tyrosine	O
phosphorylation	O
or	O
increases	O
in	O
cytoplasmic	O
free	O
calcium	O
.	O


Positive	O
and	O
negative	O
regulation	O
of	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
promoter	O
activity	O
by	O
AML1-related	B-protein
transcription	I-protein
factor	I-protein
,	O
PEBP2	B-protein
.	O


There	O
are	O
at	O
least	O
two	O
genes	O
,	O
alpha	B-DNA
A	I-DNA
and	O
alpha	B-DNA
B	I-DNA
,	O
encoding	O
the	O
alpha	B-protein
subunit	I-protein
.	O


PEBP2	B-protein
alpha	I-protein
A1	I-protein
and	O
alpha	B-protein
B1	I-protein
enhanced	O
the	O
expression	O
of	O
the	O
GM-CSF	B-DNA
promoter-driven	I-DNA
reporter	I-DNA
plasmid	I-DNA
in	O
unstimulated	B-cell_line
and	I-cell_line
12-O-tetradecanoylphorbol	I-cell_line
13-acetate/phytohemagglutinin-stimulated	I-cell_line
human	I-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O


Coexpression	O
of	O
alpha	B-protein
B1	I-protein
and	O
alpha	B-protein
B2	I-protein
showed	O
that	O
the	O
promoter	O
activity	O
could	O
be	O
determined	O
by	O
the	O
alpha	B-protein
B1	I-protein
/alpha	B-protein
B2	I-protein
ratio	O
.	O


Although	O
further	O
studies	O
are	O
required	O
to	O
determine	O
the	O
precise	O
role	O
of	O
PEBP2	B-protein
in	O
the	O
GM-CSF	B-protein
promoter	O
activity	O
,	O
the	O
present	O
findings	O
suggested	O
the	O
importance	O
of	O
the	O
relative	O
ratio	O
of	O
different	O
PEBP2	B-protein
isoforms	I-protein
in	O
regulating	O
the	O
levels	O
of	O
the	O
promoter	O
activity	O
.	O


The	O
induction	O
of	O
cytokine	B-protein
expression	O
in	O
monocytes	B-cell_type
/	O
macrophages	B-cell_type
by	O
bacterial	B-protein
endotoxin	I-protein
or	O
lipopolysaccharide	O
is	O
a	O
critical	O
,	O
highly	O
regulated	O
host	O
defence	O
response	O
.	O


IFN-gamma	B-protein
pre-treatment	O
affected	O
the	O
magnitude	O
rather	O
than	O
the	O
sensitivity	O
of	O
the	O
LPS	O
response	O
.	O


The	O
increased	O
transcriptional	O
rate	O
correlated	O
with	O
a	O
marked	O
increase	O
in	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
activity	O
in	O
these	O
cells	O
as	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
a	O
consensus	B-DNA
NF-kappa	I-DNA
B	I-DNA
oligonucleotide	I-DNA
.	O


An	O
additional	O
significant	O
finding	O
was	O
than	O
TNF	B-RNA
mRNA	I-RNA
induced	O
in	O
primed	B-cell_line
cells	I-cell_line
was	O
much	O
more	O
stable	O
than	O
in	O
unprimed	B-cell_line
cells	I-cell_line
(	O
T1/2	O
increased	O
6-8-fold	O
)	O
.	O


Consistent	O
with	O
the	O
increased	O
mRNA	B-RNA
stability	O
,	O
the	O
duration	O
of	O
mRNA	B-RNA
accumulation	O
was	O
longer	O
following	O
LPS	O
stimulation	O
in	O
primed	O
monocytes	B-cell_type
,	O
in	O
addition	O
to	O
being	O
of	O
greater	O
magnitude	O
.	O


In	O
this	O
report	O
,	O
we	O
show	O
that	O
the	O
minimal	O
CD4	B-DNA
promoter	I-DNA
has	O
four	O
factor	B-DNA
binding	I-DNA
sites	I-DNA
,	O
each	O
of	O
which	O
is	O
required	O
for	O
full	O
function	O
.	O


Using	O
biochemical	O
and	O
mutagenesis	O
analyses	O
,	O
we	O
determined	O
that	O
multiple	O
nuclear	B-protein
factors	I-protein
bind	O
to	O
these	O
independent	O
sites	O
.	O


We	O
therefore	O
believe	O
that	O
the	O
MAZ	B-protein
transcription	I-protein
factor	I-protein
is	O
also	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
control	O
of	O
developmental	O
expression	O
of	O
the	O
CD4	B-DNA
gene	I-DNA
.	O


Activation	O
of	O
the	O
TAL1	B-DNA
(	I-DNA
or	I-DNA
SCL	I-DNA
)	I-DNA
gene	I-DNA
,	O
originally	O
identified	O
through	O
its	O
involvement	O
by	O
a	O
recurrent	O
chromosomal	O
translocation	O
,	O
is	O
the	O
most	O
frequent	O
molecular	O
lesion	O
recognized	O
in	O
T-cell	O
acute	O
lymphoblastic	O
leukemia	O
.	O


The	O
protein	B-protein
products	I-protein
of	O
this	O
gene	O
contain	O
the	O
basic-helix-loop-helix	B-protein
motif	I-protein
characteristic	O
of	O
a	O
large	O
family	O
of	O
transcription	B-protein
factors	I-protein
that	O
bind	O
to	O
the	O
canonical	B-DNA
DNA	I-DNA
sequence	I-DNA
CANNTG	I-DNA
as	O
protein	B-protein
heterodimers	I-protein
.	O


Nonradioactive	O
quantification	O
of	O
glucocorticoid	B-protein
receptor	I-protein
expression	O
during	O
differentiation	O
of	O
human	O
monocytic	B-cell_type
cells	I-cell_type
(	O
U937	B-cell_line
)	O
.	O


We	O
describe	O
a	O
method	O
for	O
relative	O
quantification	O
of	O
specific	O
mRNA	B-RNA
using	O
a	O
nonradioactive	O
assay	O
based	O
on	O
DNA	O
strand	O
competition	O
between	O
identical	O
sequences	O
of	O
biotin-	O
and	O
fluorescein-labeled	O
amplicon	O
(	O
probe	O
)	O
and	O
unlabeled	O
amplicon	O
(	O
target	O
)	O
during	O
hybridization	O
.	O


This	O
technique	O
was	O
successfully	O
applied	O
to	O
evaluate	O
differences	O
in	O
glucocorticoid	B-protein
receptor	I-protein
expression	O
in	O
U937	B-cell_line
cells	I-cell_line
before	O
and	O
after	O
the	O
addition	O
of	O
potent	O
differentiation	O
inducers	O
:	O
12-O-tetradecanoylphorbol	O
13-acetate	O
(	O
TPA	O
)	O
and	O
a	O
combination	O
of	O
all-trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
and	O
1	O
,	O
25-dihydroxyvitamin	O
D2	O
(	O
VD	O
)	O
.	O


In	O
contrast	O
to	O
the	O
purely	O
enhancer-dependent	O
effect	O
of	O
cytokines	B-protein
such	O
as	O
TNF	B-protein
on	O
the	O
activity	O
of	O
the	O
HIV	B-DNA
regulatory	I-DNA
region	I-DNA
(	O
LTR	B-DNA
)	O
,	O
we	O
observed	O
that	O
okadaic	O
acid	O
(	O
OKA	O
)	O
activates	O
HIV	O
transcription	O
through	O
both	O
the	O
enhancer	O
,	O
responding	O
to	O
the	O
factor	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
the	O
promoter	B-DNA
domain	I-DNA
of	O
the	O
LTR	B-DNA
.	O


In	O
both	O
transformed	B-cell_type
and	I-cell_type
normal	I-cell_type
lymphocytes	I-cell_type
,	O
OKA	O
stimulation	O
induced	O
intense	O
phosphorylation	O
of	O
the	O
constitutively	O
expressed	O
Sp1	B-protein
protein	I-protein
in	O
the	O
nucleus	O
,	O
a	O
property	O
of	O
OKA	O
not	O
shared	O
by	O
TNF	B-protein
,	O
phorbol	O
ester	O
,	O
or	O
PHA	B-protein
and	O
interleukin	B-protein
2	I-protein
.	O


Responsiveness	O
of	O
LTR	B-DNA
constructs	I-DNA
deleted	O
of	O
kappa	B-DNA
B	I-DNA
elements	I-DNA
to	O
HIV	B-protein
Tat	I-protein
expression	O
was	O
increased	O
upon	O
OKA	O
but	O
not	O
TNF	B-protein
stimulation	O
.	O


Our	O
results	O
suggest	O
that	O
SP1	B-protein
phosphorylation	O
induced	O
by	O
OKA	O
,	O
a	O
selective	O
inhibitor	O
of	O
the	O
serine-threonine	B-protein
phosphatase	I-protein
PP2A	B-protein
,	O
facilitates	O
the	O
formation	O
of	O
a	O
transcription	B-protein
complex	I-protein
involving	O
general	O
transcription	B-protein
factors	I-protein
,	O
HIV	B-protein
Tat	I-protein
,	O
and	O
Sp1	B-protein
proteins	I-protein
.	O


Interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
rapidly	O
activated	O
Stat5	B-protein
in	O
fresh	O
PBL	B-cell_type
,	O
and	O
Stat3	B-protein
and	O
Stat5	B-protein
in	O
preactivated	B-cell_type
PBL	I-cell_type
.	O


IL-7	B-protein
and	O
IL-15	B-protein
induced	O
the	O
same	O
complexes	O
as	O
IL-2	B-protein
,	O
a	O
feature	O
explained	O
by	O
the	O
existence	O
of	O
similar	O
tyrosine-phosphorylated	B-protein
motifs	I-protein
in	O
the	O
cytoplasmic	B-protein
domains	I-protein
of	O
IL-2R	B-protein
beta	I-protein
and	O
IL-7R	B-protein
that	O
can	O
serve	O
as	O
docking	O
sites	O
for	O
Stat	B-protein
proteins	I-protein
.	O


These	O
studies	O
demonstrate	O
that	O
a	O
single	O
cytokine	B-protein
can	O
activate	O
different	O
combinations	O
of	O
Stat	B-protein
proteins	I-protein
under	O
different	O
physiological	O
conditions	O
,	O
and	O
also	O
indicate	O
two	O
mechanisms	O
by	O
which	O
distinct	O
cytokines	B-protein
can	O
activate	O
the	O
same	O
Stat	B-protein
protein	I-protein
.	O


Various	O
stimuli	O
,	O
typically	O
those	O
associated	O
with	O
stress	O
or	O
pathogens	O
,	O
rapidly	O
inactivate	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
.	O


When	O
either	O
serine-32	O
or	O
serine-36	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
was	O
mutated	O
,	O
the	O
protein	O
did	O
not	O
undergo	O
signal-induced	O
phosphorylation	O
or	O
degradation	O
,	O
and	O
NF-kappa	B-protein
B	I-protein
could	O
not	O
be	O
activated	O
.	O


We	O
used	O
deletion	O
analysis	O
and	O
transfection	O
assays	O
with	O
reporter	B-DNA
gene	I-DNA
constructs	I-DNA
to	O
examine	O
the	O
transcription	B-DNA
control	I-DNA
elements	I-DNA
in	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
of	O
the	O
human	B-DNA
EpoR	I-DNA
gene	I-DNA
.	O


The	O
150	B-DNA
bp	I-DNA
hEpoR	I-DNA
promoter	I-DNA
exhibited	O
high	O
and	O
low	O
activity	O
in	O
erythroid	O
OCIM1	B-cell_line
and	O
K562	B-cell_line
cells	I-cell_line
,	O
respectively	O
,	O
reflecting	O
the	O
high	O
and	O
low	O
levels	O
of	O
constitutive	O
hEpoR	B-protein
expression	O
.	O


By	O
increasing	O
GATA-1	B-protein
levels	O
via	O
co-transfection	O
,	O
we	O
were	O
able	O
to	O
transactivate	O
the	O
hEpoR	B-DNA
promoter	I-DNA
in	O
K562	B-cell_line
cells	I-cell_line
and	O
non-erythroid	B-cell_type
cells	I-cell_type
,	O
but	O
not	O
in	O
the	O
highly	O
active	O
OCIM1	B-cell_type
cells	I-cell_type
,	O
although	O
GATA-1	B-RNA
mRNA	I-RNA
levels	O
were	O
comparable	O
in	O
OCIM1	B-cell_line
and	O
K562	B-cell_line
.	O


These	O
data	O
suggest	O
that	O
while	O
GATA-1	B-protein
can	O
transactivate	O
the	O
EpoR	B-DNA
promoter	I-DNA
,	O
the	O
level	O
of	O
hEpoR	B-DNA
gene	I-DNA
expression	O
does	O
not	O
depend	O
on	O
GATA-1	B-protein
alone	O
.	O


The	O
deduced	O
amino	O
acid	O
sequence	O
similarity	O
to	O
the	O
proteins	O
encoded	O
by	O
these	O
two	O
latter	O
genes	O
is	O
approximately	O
65	O
%	O
and	O
includes	O
domains	O
and	O
amino	O
acid	O
residues	O
(	O
the	O
leucine	B-protein
zipper-like	I-protein
and	O
the	O
RGD	B-protein
domain	I-protein
,	O
a	O
serine	O
and	O
a	O
histidine	O
residue	O
in	O
the	O
NH2-	B-protein
and	O
in	O
the	O
COOH-terminal	B-protein
portion	I-protein
of	O
the	O
protein	O
,	O
respectively	O
)	O
postulated	O
to	O
be	O
important	O
for	O
nm23	B-protein
function	O
.	O


An	O
interferon-gamma	B-DNA
activation	I-DNA
sequence	I-DNA
mediates	O
the	O
transcriptional	O
regulation	O
of	O
the	O
IgG	B-DNA
Fc	I-DNA
receptor	I-DNA
type	I-DNA
IC	I-DNA
gene	I-DNA
by	O
interferon-gamma	B-protein
.	O


Expression	O
of	O
the	O
IgG	B-protein
Fc	I-protein
receptor	I-protein
type	I-protein
I	I-protein
(	O
Fc	B-protein
gamma	I-protein
RI	I-protein
)	O
on	O
myeloid	B-cell_type
cells	I-cell_type
is	O
dramatically	O
increased	O
by	O
treatment	O
with	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
.	O


We	O
observed	O
that	O
Fc	B-protein
gamma	I-protein
RI	I-protein
transcript	O
levels	O
in	O
monoblast-like	B-cell_line
U937	I-cell_line
cells	I-cell_line
were	O
elevated	O
within	O
3	O
hr	O
and	O
peaked	O
12	O
hr	O
after	O
exposure	O
to	O
IFN-gamma	B-protein
.	O


Double-stranded	B-DNA
GIRE	I-DNA
sequence	I-DNA
,	O
but	O
not	O
a	O
scrambled	B-DNA
sequence	I-DNA
,	O
was	O
specifically	O
bound	O
by	O
nuclear	B-protein
proteins	I-protein
from	O
IFN-gamma	B-cell_line
treated	I-cell_line
U937	I-cell_line
cells	I-cell_line
.	O


The	O
Fc	B-DNA
gamma	I-DNA
RIC	I-DNA
GIRE	I-DNA
is	O
homologous	O
to	O
the	O
IFN-gamma	B-DNA
activation	I-DNA
sequence	I-DNA
(	O
GAS	B-DNA
)	O
of	O
the	O
guanylate	B-protein
binding	I-protein
protein	I-protein
and	O
to	O
X	B-DNA
box	I-DNA
elements	I-DNA
of	O
class	B-DNA
II	I-DNA
MHC	I-DNA
genes	I-DNA
.	O


HTLV-I-infected	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
exhibit	O
an	O
initial	O
phase	O
of	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
-dependent	O
growth	O
;	O
over	O
time	O
,	O
by	O
an	O
unknown	O
mechanism	O
,	O
the	O
cells	O
become	O
IL-2	B-protein
-independent	O
.	O


In	O
HTLV-I-infected	B-cell_line
cord	I-cell_line
blood	I-cell_line
lymphocytes	I-cell_line
,	O
the	O
transition	O
from	O
IL-2	B-protein
-dependent	O
to	O
IL-2	B-protein
-independent	O
growth	O
correlated	O
with	O
the	O
acquisition	O
of	O
a	O
constitutively	O
activated	O
Jak	B-protein
-STAT	B-protein
pathway	O
,	O
which	O
suggests	O
that	O
this	O
pathway	O
participates	O
in	O
HTLV-I-mediated	O
T	O
cell	O
transformation	O
.	O


Nitric	O
oxide	O
decreases	O
cytokine	B-protein
-induced	O
endothelial	O
activation	O
.	O


In	O
a	O
concentration-dependent	O
manner	O
,	O
NO	O
inhibited	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-1	I-protein
alpha-stimulated	O
VCAM-1	B-protein
expression	O
by	O
35-55	O
%	O
as	O
determined	O
by	O
cell	O
surface	O
enzyme	O
immunoassays	O
and	O
flow	O
cytometry	O
.	O


NO	O
also	O
decreased	O
the	O
endothelial	O
expression	O
of	O
other	O
leukocyte	B-protein
adhesion	I-protein
molecules	I-protein
(	O
E-selectin	B-protein
and	O
to	O
a	O
lesser	O
extent	O
,	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
)	O
and	O
secretable	O
cytokines	B-protein
(	O
IL-6	B-protein
and	O
IL-8	B-protein
)	O
.	O


Nuclear	O
run-on	O
assays	O
,	O
transfection	O
studies	O
using	O
various	O
VCAM-1	B-DNA
promoter	I-DNA
reporter	I-DNA
gene	I-DNA
constructs	I-DNA
,	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
indicated	O
that	O
NO	O
represses	O
VCAM-1	B-protein
gene	O
transcription	O
,	O
in	O
part	O
,	O
by	O
inhibiting	O
NF-kappa	B-protein
B	I-protein
.	O


It	O
also	O
induces	O
chemotaxis	O
and	O
inflammatory	O
responses	O
in	O
mature	B-cell_type
cell	I-cell_type
types	I-cell_type
.	O


Therefore	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
mechanisms	O
which	O
control	O
the	O
expression	O
of	O
MIP-1	B-protein
alpha	I-protein
/GOS19	B-protein
.	O


Previous	O
work	O
has	O
shown	O
that	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
a	O
set	O
of	O
widely	O
expressed	O
transcription	B-protein
factors	I-protein
(	O
the	O
ICK-1	B-protein
family	I-protein
)	O
affect	O
the	O
GOS19	B-DNA
promoter	I-DNA
.	O


In	O
this	O
communication	O
,	O
we	O
provide	O
evidence	O
that	O
the	O
pathway	O
of	O
induction	O
in	O
the	O
macrophage	B-cell_line
cell	I-cell_line
line	I-cell_line
U937	B-cell_line
is	O
different	O
from	O
that	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O


We	O
provide	O
evidence	O
for	O
an	O
additional	O
binding	B-DNA
site	I-DNA
,	O
the	O
MIP-1	B-DNA
alpha	I-DNA
nuclear	I-DNA
protein	I-DNA
(	I-DNA
MNP	I-DNA
)	I-DNA
site	I-DNA
,	O
which	O
overlaps	O
the	O
ICK-1	B-DNA
site	I-DNA
.	O


A	O
mutation	O
of	O
the	O
MNP	B-DNA
site	I-DNA
which	O
does	O
not	O
abrogate	O
ICK-1	O
binding	O
inactivates	O
the	O
GOS19.1	B-DNA
promoter	I-DNA
in	O
U937	B-cell_line
cells	I-cell_line
and	O
reduces	O
its	O
activity	O
by	O
fourfold	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O


We	O
propose	O
that	O
the	O
MNP	B-protein
protein	I-protein
(	O
s	O
)	O
binding	O
at	O
the	O
MNP	B-DNA
site	I-DNA
constitutes	O
a	O
novel	O
transcription	B-protein
factor	I-protein
(	O
s	O
)	O
expressed	O
in	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O


Toremifene	O
exerts	O
multiple	O
and	O
varied	O
effects	O
on	O
the	O
gene	O
expression	O
of	O
human	B-cell_type
peripheral	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O


The	O
interleukin-5	B-protein
/receptor	O
interaction	O
activates	O
Lyn	B-protein
and	I-protein
Jak2	I-protein
tyrosine	I-protein
kinases	I-protein
and	O
propagates	O
signals	O
via	O
the	O
Ras-Raf-1-MAP	B-protein
kinase	I-protein
and	O
the	O
Jak	B-protein
-STAT	B-protein
pathways	O
in	O
eosinophils	B-cell_type
.	O


IL-5	B-protein
also	O
stimulates	O
GTP	O
binding	O
to	O
p21ras	B-protein
.	O


Jak2	B-protein
kinase	I-protein
has	O
been	O
shown	O
to	O
phosphorylate	O
STAT	B-protein
nuclear	I-protein
proteins	I-protein
.	O


The	O
IE2	B-protein
gene	I-protein
product	I-protein
of	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
is	O
one	O
of	O
a	O
few	O
viral	B-protein
regulatory	I-protein
proteins	I-protein
expressed	O
immediately	O
upon	O
infection	O
of	O
the	O
host	B-cell_type
cell	I-cell_type
.	O


It	O
is	O
a	O
potent	O
transcriptional	B-protein
activator	I-protein
of	O
many	O
viral	B-DNA
and	I-DNA
cellular	I-DNA
promoters	I-DNA
.	O


However	O
,	O
unlike	O
another	O
tumor	B-protein
suppressor	I-protein
protein	I-protein
,	O
p53	B-protein
,	O
Rb	B-protein
did	O
not	O
have	O
any	O
significant	O
effect	O
on	O
basal	O
levels	O
of	O
transcription	O
,	O
suggesting	O
that	O
Rb	B-protein
specifically	O
interacts	O
with	O
IE2	B-protein
rather	O
than	O
other	O
cellular	B-protein
factors	I-protein
involved	O
in	O
the	O
general	O
transcription	O
machinery	O
.	O


Our	O
results	O
suggest	O
that	O
Rb	B-protein
may	O
regulate	O
the	O
life	O
cycle	O
of	O
HCMV	O
,	O
which	O
is	O
endemic	O
in	O
the	O
human	O
population	O
.	O


In	O
order	O
to	O
determine	O
whether	O
NDP	B-protein
kinase	I-protein
expression	O
serves	O
as	O
a	O
marker	O
for	O
metastatic	O
potential	O
in	O
human	O
skin	O
cancer	O
,	O
we	O
assessed	O
the	O
levels	O
of	O
NDP	B-protein
kinase	I-protein
expression	O
in	O
9	O
keratoacanthomas	O
(	O
KAs	O
)	O
,	O
26	O
squamous	O
cell	O
carcinomas	O
(	O
SCCs	O
)	O
,	O
and	O
25	O
basal	O
cell	O
carcinomas	O
(	O
BCCs	O
)	O
using	O
immunohistochemistry	O
.	O


And	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
NDP	B-protein
kinase	I-protein
expression	O
between	O
SCC	O
with	O
metastasis	O
and	O
SCC	O
without	O
metastasis	O
.	O


The	O
major	B-DNA
histocompatibility	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
encode	O
cell	B-protein
surface	I-protein
proteins	I-protein
that	O
bind	O
antigenic	O
peptide	O
for	O
presentation	O
to	O
T-cells	B-cell_type
.	O


The	O
class	B-protein
II	I-protein
proteins	I-protein
are	O
expressed	O
constitutively	O
on	O
B-cells	B-cell_type
and	O
EBV-transformed	B-cell_line
B-cells	I-cell_line
,	I-cell_line
and	O
are	O
inducible	O
by	O
IFN-gamma	B-protein
on	O
a	O
wide	O
variety	O
of	O
cell	B-cell_type
types	I-cell_type
.	O


RB-defective	B-cell_line
tumor	I-cell_line
lines	I-cell_line
are	O
non-inducible	O
for	O
MHC	B-protein
class	I-protein
II	I-protein
by	O
IFN-gamma	B-protein
,	O
or	O
very	O
weakly	O
inducible	O
,	O
but	O
transfection	O
of	O
2	O
different	O
lines	O
with	O
RB	B-DNA
expression	I-DNA
vectors	I-DNA
re-establishes	O
or	O
substantially	O
enhances	O
class	O
II	O
inducibility	O
.	O


Nuclear	O
matrix-bound	O
RB	B-protein
was	O
detectable	O
in	O
all	O
cases	O
,	O
indicating	O
that	O
loss	O
of	O
RB	B-protein
is	O
not	O
responsible	O
for	O
decreased	O
class	O
II	O
expression	O
in	O
these	O
lines	O
.	O


CIITA	B-RNA
mRNA	I-RNA
is	O
normally	O
inducible	O
by	O
IFN-gamma	B-protein
in	O
class	B-cell_line
II	I-cell_line
non-inducible	I-cell_line
,	I-cell_line
RB-defective	I-cell_line
lines	I-cell_line
,	O
and	O
in	O
one	O
line	O
,	O
re-expression	O
of	O
RB	B-protein
has	O
no	O
effect	O
on	O
CIITA	B-RNA
mRNA	I-RNA
induction	O
levels	O
.	O


We	O
have	O
recently	O
demonstrated	O
that	O
stimulation	O
of	O
human	B-cell_type
T	I-cell_type
and	I-cell_type
natural	I-cell_type
killer	I-cell_type
cells	I-cell_type
with	O
IL-12	B-protein
induces	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	B-protein
family	I-protein
tyrosine	I-protein
kinase	I-protein
JAK2	B-protein
and	O
Tyk2	B-protein
,	O
implicating	O
these	O
kinases	B-protein
in	O
the	O
immediate	O
biochemical	O
response	O
to	O
IL-12	B-protein
.	O


Recently	O
,	O
transcription	B-protein
factors	I-protein
known	O
as	O
STATs	B-protein
(	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
)	O
have	O
been	O
shown	O
to	O
be	O
tyrosine	O
phosphorylated	O
and	O
activated	O
in	O
response	O
to	O
a	O
number	O
of	O
cytokines	B-protein
that	O
bind	O
hematopoietin	B-protein
receptors	I-protein
and	O
activate	O
JAK	B-protein
kinases	I-protein
.	O


Furthermore	O
,	O
we	O
show	O
that	O
IL-12	B-protein
stimulates	O
formation	O
of	O
a	O
DNA-binding	B-protein
complex	I-protein
that	O
recognizes	O
a	O
DNA	O
sequence	O
previously	O
shown	O
to	O
bind	O
STAT	B-protein
proteins	I-protein
and	O
that	O
this	O
complex	O
contains	O
STAT4	B-protein
.	O


We	O
have	O
studied	O
the	O
adaptive	O
mechanisms	O
which	O
occur	O
at	O
the	O
level	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
in	O
glucocorticoid	O
target	O
tissues	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O


RESULTS	O
:	O
Hypercortisolaemia	O
,	O
in	O
vitro	O
,	O
resulted	O
in	O
a	O
decreased	O
affinity	O
and	O
a	O
decreased	O
binding	O
capacity	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O


There	O
was	O
a	O
weak	O
but	O
significant	O
negative	O
correlation	O
between	O
body	O
temperature	O
and	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
the	O
patient	O
group	O
.	O


CONCLUSIONS	O
:	O
There	O
is	O
no	O
obvious	O
regulation	O
of	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
by	O
plasma	O
cortisol	O
concentrations	O
in	O
vivo	O
.	O


Integrin-mediated	O
tyrosine	O
phosphorylation	O
and	O
cytokine	B-protein
message	O
induction	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O


Activation	O
of	O
cytoplasmic	B-protein
tyrosine	I-protein
kinases	I-protein
is	O
an	O
important	O
aspect	O
of	O
signal	O
transduction	O
mediated	O
by	O
integrins	B-protein
.	O


In	O
addition	O
,	O
integrin	B-protein
ligation	O
leads	O
to	O
nuclear	O
translocation	O
of	O
the	O
p50	B-protein
and	O
p65	B-protein
subunits	I-protein
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
,	O
to	O
activation	O
of	O
a	O
reporter	B-DNA
gene	I-DNA
driven	O
by	O
a	O
promoter	B-DNA
containing	O
NF-kappa	B-DNA
B	I-DNA
sites	I-DNA
,	O
and	O
to	O
increased	O
levels	O
of	O
mRNAs	B-RNA
for	O
immediate-early	B-DNA
genes	I-DNA
,	O
including	O
the	O
cytokine	B-protein
interleukin	I-protein
(	I-protein
IL	I-protein
)	I-protein
-1	I-protein
beta	I-protein
.	O


These	O
observations	O
indicate	O
that	O
the	O
Syk	B-protein
tyrosine	O
kinase	O
may	O
be	O
an	O
important	O
component	O
of	O
an	O
integrin	B-protein
signaling	O
pathway	O
in	O
monocytic	B-cell_type
cells	I-cell_type
,	O
leading	O
to	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
to	O
increased	O
levels	O
of	O
cytokine	B-protein
messages	O
.	O


To	O
determine	O
if	O
New	O
World	O
primates	O
express	O
an	O
inhibitor	O
that	O
influences	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
binding	O
characteristics	O
,	O
we	O
examined	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
in	O
cytosol	O
prepared	O
from	O
B95-8	B-cell_line
lymphoid	I-cell_line
cells	I-cell_line
,	O
derived	O
from	O
the	O
cotton	O
top	O
tamarin	O
(	O
Saguinus	O
oedipus	O
)	O
,	O
in	O
combination	O
with	O
cytosol	O
prepared	O
from	O
human	O
or	O
rat	O
tissues	O
.	O


The	O
inhibitory	O
activity	O
was	O
heat	O
labile	O
and	O
trypsin	B-protein
sensitive	O
.	O


Disruption	O
of	O
a	O
GATA	B-DNA
motif	I-DNA
in	O
the	O
Duffy	B-DNA
gene	I-DNA
promoter	I-DNA
abolishes	O
erythroid	B-DNA
gene	I-DNA
expression	O
in	O
Duffy-negative	O
individuals	O
.	O


With	O
the	O
recent	O
characterization	O
of	O
the	O
FY*A	B-DNA
and	I-DNA
FY*B	I-DNA
alleles	I-DNA
,	O
these	O
findings	O
provide	O
the	O
molecular	O
basis	O
of	O
the	O
Duffy	O
blood	O
group	O
system	O
and	O
an	O
explanation	O
for	O
the	O
erythroid-specific	O
repression	O
of	O
the	O
DARC	B-DNA
gene	I-DNA
in	O
Duffy-negative	O
individuals	O
.	O


The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
pokeweed	B-protein
mitogen	I-protein
(	O
PWM	B-protein
)	O
on	O
the	O
induction	O
of	O
early	B-DNA
growth	I-DNA
response-1	I-DNA
gene	I-DNA
(	O
EGR-1	B-DNA
)	O
in	O
normal	B-cell_type
human	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O


Transient	O
transfection	O
assays	O
with	O
EGR-1	B-DNA
promoter	I-DNA
fragments	I-DNA
linked	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
gene	I-DNA
demonstrated	O
that	O
PWM	B-protein
induced	O
EGR-1	B-DNA
transcription	O
is	O
conferred	O
by	O
the	O
CArG	B-DNA
motif	I-DNA
(	O
C	B-DNA
C	I-DNA
[	I-DNA
AT	I-DNA
]	I-DNA
6GG	I-DNA
)	O
in	O
the	O
EGR-1	B-DNA
promoter	I-DNA
.	O


A	O
conserved	B-DNA
motif	I-DNA
in	O
the	O
promoters	B-DNA
of	O
several	O
cytokines	B-protein
expressed	O
by	O
human	B-cell_line
Th2-type	I-cell_line
lymphocytes	I-cell_line
.	O


This	O
suggest	O
that	O
they	O
may	O
interact	O
with	O
a	O
new	O
family	O
of	O
trans-acting	B-protein
factors	I-protein
.	O


Considering	O
the	O
strong	O
positive	O
regulatory	O
effect	O
of	O
this	O
element	B-DNA
and	O
its	O
presence	O
in	O
several	O
T-cell-expressed	B-DNA
cytokine	I-DNA
genes	I-DNA
,	O
it	O
may	O
be	O
crucial	O
to	O
the	O
coordinated	O
expression	O
of	O
these	O
cytokines	B-protein
in	O
T	B-cell_type
helper	I-cell_type
cells	I-cell_type
.	O


A	O
human	B-cell_line
T	I-cell_line
lymphoid	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
PEER	B-cell_line
,	O
dies	O
by	O
apoptosis	O
in	O
the	O
presence	O
of	O
PMA	O
and	O
calcium	O
ionophore	O
.	O


A	O
new	O
gene	B-DNA
,	O
TINUR	B-DNA
,	O
was	O
cloned	O
from	O
apoptotic	B-cell_line
PEER	I-cell_line
cells	I-cell_line
.	O


TINUR	B-DNA
belongs	O
to	O
the	O
NGFI-B/nur77	B-protein
family	I-protein
of	O
the	O
steroid	B-protein
receptor	I-protein
superfamily	I-protein
and	O
is	O
an	O
orphan	B-protein
receptor	I-protein
.	O


BACKGROUND	O
:	O
The	O
induction	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
VCAM-1	B-protein
)	O
and	O
E-selectin	B-protein
by	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF	B-protein
)	O
is	O
mediated	O
by	O
mobilization	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
.	O


Since	O
salicylates	O
have	O
been	O
reported	O
to	O
inhibit	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
preventing	O
the	O
degradation	O
of	O
its	O
inhibitor	O
I	B-protein
kappa	I-protein
B	I-protein
,	O
we	O
studied	O
a	O
potential	O
inhibition	O
of	O
this	O
pathway	O
by	O
acetylsalicylate	O
(	O
aspirin	O
)	O
in	O
human	B-cell_line
umbilical	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
(	O
HUVECs	B-cell_line
)	O
.	O


Induction	O
of	O
VCAM-1	B-protein
and	O
E-selectin	B-protein
surface	O
expression	O
by	O
TNF	B-protein
was	O
dose-dependently	O
reduced	O
by	O
aspirin	O
over	O
the	O
same	O
range	O
,	O
while	O
induction	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
(	O
ICAM-1	B-protein
)	O
was	O
hardly	O
affected	O
.	O


CONCLUSIONS	O
:	O
Our	O
data	O
suggest	O
that	O
aspirin	O
inhibits	O
NF-kappa	B-protein
B	I-protein
mobilization	O
,	O
induction	O
of	O
VCAM-1	B-protein
and	O
E-selectin	B-protein
,	O
and	O
subsequent	O
monocyte	O
adhesion	O
in	O
endothelial	B-cell_type
cells	I-cell_type
stimulated	O
by	O
TNF	B-protein
,	O
thereby	O
providing	O
an	O
additional	O
mechanism	O
for	O
therapeutic	O
effects	O
of	O
aspirin	O
.	O


Activation	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
phosphatase	B-protein
inhibitors	O
involves	O
the	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
at	O
phosphatase	B-protein
2A-sensitive	I-protein
sites	I-protein
.	O


In	O
the	O
present	O
study	O
,	O
the	O
role	O
of	O
serine/threonine	B-protein
phosphatases	I-protein
in	O
the	O
regulation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
phosphorylation	O
was	O
investigated	O
.	O


Furthermore	O
,	O
the	O
phosphorylated	B-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
from	O
calyculin	B-cell_line
A-treated	I-cell_line
cells	I-cell_line
,	O
but	O
not	O
that	O
from	O
TNF-alpha-stimulated	B-cell_line
cells	I-cell_line
,	O
is	O
sensitive	O
to	O
PP-2A	B-protein
in	O
vitro	O
,	O
suggesting	O
the	O
existence	O
of	O
fundamental	O
differences	O
in	O
the	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
induced	O
by	O
the	O
two	O
different	O
NF-kappa	B-protein
B	I-protein
inducers	O
.	O


Together	O
,	O
these	O
results	O
suggest	O
that	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
mediated	O
through	O
both	O
the	O
TNF-alpha	B-protein
-inducible	O
and	O
the	O
PP-2A-opposing	B-protein
kinases	I-protein
,	O
may	O
serve	O
to	O
target	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
for	O
proteasome	B-protein
-mediated	O
degradation	O
.	O


Sp1	B-protein
functions	O
in	O
a	O
chromatin	B-DNA
-dependent	O
manner	O
to	O
augment	O
human	B-DNA
alpha-globin	I-DNA
promoter	I-DNA
activity	O
.	O


The	O
5	B-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
of	O
the	O
human	B-DNA
alpha-globin	I-DNA
gene	I-DNA
is	O
highly	O
G	O
+	O
C	O
rich	O
and	O
contains	O
multiple	O
copies	O
of	O
the	O
consensus	B-DNA
sequence	I-DNA
for	O
the	O
Sp1	B-DNA
binding	I-DNA
site	I-DNA
.	O


However	O
,	O
upon	O
stable	O
integration	O
into	O
chromatin	B-DNA
,	O
deletion	O
of	O
this	O
region	O
causes	O
a	O
nearly	O
90	O
%	O
decrease	O
in	O
promoter	O
activity	O
compared	O
with	O
expression	O
from	O
an	O
alpha-globin	B-DNA
promoter	I-DNA
retaining	O
this	O
region	O
.	O


We	O
have	O
earlier	O
shown	O
that	O
stimulation	O
of	O
human	B-cell_line
CD4+	I-cell_line
T	I-cell_line
cells	I-cell_line
with	O
SEA	O
presented	O
on	O
Chinese	B-cell_line
hamster	I-cell_line
ovary	I-cell_line
(	I-cell_line
CHO	I-cell_line
)	I-cell_line
-DR	I-cell_line
transfectants	I-cell_line
coexpressing	O
either	O
B7	B-protein
or	O
LFA-3	B-protein
resulted	O
in	O
distinct	O
cytokine	B-protein
profiles	O
.	O


LFA-3	B-protein
induced	O
moderate	O
levels	O
of	O
AP-1	B-protein
,	O
but	O
did	O
not	O
influence	O
the	O
levels	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
while	O
B7	B-protein
costimulation	O
strongly	O
induced	O
both	O
AP-1	B-protein
and	O
substantially	O
enhanced	O
NF-kappa	B-protein
B	I-protein
binding	I-protein
proteins	I-protein
.	O


The	O
CHO-DR/B7/LFA-3	B-cell_line
triple	I-cell_line
transfectant	I-cell_line
induced	O
a	O
further	O
increase	O
in	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
binding	B-protein
proteins	I-protein
compared	O
with	O
the	O
double	B-cell_line
transfectants	I-cell_line
.	O


The	O
AP-1	B-protein
binding	I-protein
proteins	I-protein
contained	O
c-Jun	B-protein
,	O
Jun-D	B-protein
,	O
and	O
Fra-1	B-protein
,	O
but	O
marginal	O
amounts	O
of	O
Jun-B	B-protein
and	O
c-Fos	B-protein
.	O


The	O
Ah	B-protein
receptor	I-protein
recognizes	O
DNA	B-DNA
binding	I-DNA
sites	I-DNA
for	O
the	O
B	B-protein
cell	I-protein
transcription	I-protein
factor	I-protein
,	O
BSAP	B-protein
:	O
a	O
possible	O
mechanism	O
for	O
dioxin-mediated	O
alteration	O
of	O
CD19	B-DNA
gene	I-DNA
expression	O
in	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O


Using	O
a	O
gel	O
mobility	O
shift	O
assay	O
,	O
we	O
identified	O
a	O
DNA-binding	B-protein
complex	I-protein
in	O
IM-9	O
nuclear	O
extracts	O
that	O
by	O
several	O
criteria	O
appears	O
to	O
be	O
the	O
Ah	B-protein
receptor	I-protein
.	O


These	O
results	O
suggest	O
that	O
the	O
AhR	B-protein
could	O
interfere	O
with	O
BSAP	B-protein
-stimulated	O
CD19	B-DNA
gene	I-DNA
transcription	O
by	O
competition	O
for	O
a	O
common	O
DNA	B-DNA
binding	I-DNA
site	I-DNA
.	O


Inhibitory	O
action	O
of	O
nm23	B-protein
proteins	I-protein
on	O
induction	O
of	O
erythroid	O
differentiation	O
of	O
human	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O


We	O
recently	O
identified	O
a	O
differentiation	B-protein
inhibitory	I-protein
factor	I-protein
(	O
I-factor	B-protein
)	O
in	O
mouse	B-cell_line
myeloid	I-cell_line
leukemia	I-cell_line
M1	I-cell_line
cells	I-cell_line
as	O
a	O
murine	B-protein
homolog	I-protein
of	O
the	O
human	B-protein
nm23-H2	I-protein
gene	I-protein
product	I-protein
.	O


nm23	B-DNA
genes	I-DNA
encode	O
proteins	O
that	O
participate	O
in	O
tumor	O
metastasis	O
regulation	O
and	O
in	O
various	O
fundamental	O
cellular	O
processes	O
,	O
although	O
their	O
mechanisms	O
of	O
action	O
are	O
still	O
unknown	O
.	O


Lipopolysaccharide-induced	O
E-selectin	B-protein
expression	O
requires	O
continuous	O
presence	O
of	O
LPS	O
and	O
is	O
inhibited	O
by	O
bactericidal/permeability-increasing	B-protein
protein	I-protein
.	O


rBPI21	B-protein
,	O
a	O
recombinant	B-protein
N-terminal	I-protein
fragment	I-protein
of	O
human	B-protein
bactericidal/permeability-increasing	I-protein
protein	I-protein
(	O
BPI	B-protein
)	O
,	O
inhibited	O
LPS-induced	O
E-selectin	B-protein
expression	O
when	O
added	O
at	O
the	O
same	O
time	O
as	O
,	O
and	O
up	O
to	O
6	O
h	O
after	O
,	O
LPS	O
.	O


Two	O
to	O
4	O
h	O
following	O
LPS	O
addition	O
to	O
endothelial	B-cell_type
cells	I-cell_type
,	O
when	O
NF-kappa	B-protein
B	I-protein
was	O
already	O
activated	O
,	O
addition	O
of	O
rBPI21	B-protein
resulted	O
in	O
marked	O
reduction	O
of	O
NF-kappa	B-protein
B	I-protein
detectable	O
at	O
4	O
or	O
6	O
h	O
.	O


So	O
called	O
costimulatory	O
signals	O
,	O
mediated	O
by	O
other	O
cell	O
surface	O
interactions	O
or	O
soluble	B-protein
cytokines	I-protein
produced	O
by	O
antigen	B-cell_type
presenting	I-cell_type
cells	I-cell_type
,	O
are	O
also	O
required	O
for	O
complete	O
T	O
cell	O
activation	O
.	O


These	O
promoter	B-DNA
and	I-DNA
enhancer	I-DNA
regions	I-DNA
are	O
mainly	O
activated	O
by	O
the	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
.	O


The	O
activation	O
of	O
NFAT	B-protein
by	O
TCR	B-protein
signals	O
has	O
been	O
well	O
described	O
for	O
interleukin-2	O
(	O
IL-2	B-protein
)	O
and	O
IL-4	O
gene	O
transcription	O
in	O
T	B-cell_type
cells	I-cell_type
.	O


We	O
have	O
found	O
that	O
the	O
HTLV-1	B-protein
transactivator	I-protein
protein	I-protein
,	O
tax	B-protein
,	O
acts	O
as	O
a	O
costimulatory	O
signal	O
for	O
GM-CSF	O
and	O
IL-2	O
gene	O
transcription	O
,	O
in	O
that	O
it	O
can	O
cooperate	O
with	O
TCR	B-protein
signals	O
to	O
mediate	O
high	O
level	O
gene	O
expression	O
.	O


This	O
observation	O
,	O
together	O
with	O
the	O
fact	O
that	O
both	O
GM-CSF	B-protein
and	O
IL-2	B-protein
respond	O
to	O
TCR	B-protein
signals	O
via	O
NFAT	B-protein
,	O
implies	O
a	O
high	O
degree	O
of	O
conservation	O
in	O
the	O
regulation	O
of	O
cytokine	B-protein
gene	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O


At	O
10	O
microM	O
,	O
both	O
compounds	O
inhibited	O
IL-2	O
mRNA	O
and	O
protein	O
levels	O
in	O
the	O
NFAT-1-linked	B-cell_line
lac-Z	I-cell_line
transfectants	I-cell_line
,	O
and	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
.	O


Both	O
compounds	O
inhibited	O
the	O
mixed	O
lymphocyte	O
reaction	O
,	O
and	O
this	O
inhibition	O
was	O
reversed	O
by	O
exogenous	O
IL-2	B-protein
.	O


Conversely	O
,	O
calcium-independent	B-protein
anti-CD28	I-protein
Ab	I-protein
and	O
PMA-induced	O
IL-2	B-protein
production	O
was	O
resistant	O
.	O


By	O
these	O
functional	O
criteria	O
,	O
we	O
believe	O
we	O
have	O
identified	O
two	O
structurally	O
distinct	O
,	O
novel	O
inhibitors	O
of	O
NFAT	B-protein
-1-mediated	O
transcription	O
.	O


From	O
nuclear	O
runoff	O
experiments	O
,	O
we	O
found	O
that	O
one	O
subunit	O
in	O
particular	O
,	O
the	O
B2	B-protein
isoform	I-protein
(	O
Mr	O
=	O
56	O
,	O
000	O
)	O
,	O
was	O
amplified	O
primarily	O
by	O
transcriptional	O
means	O
.	O


Isolation	O
and	O
sequencing	O
of	O
the	O
first	B-DNA
exon	I-DNA
and	O
5'-flanking	B-DNA
region	I-DNA
of	O
this	O
gene	O
reveal	O
a	O
TATA-less	B-DNA
promoter	I-DNA
with	O
a	O
high	O
G	O
+	O
C	O
content	O
.	O


Okadaic	O
acid	O
augments	O
PMA-	O
as	O
well	O
as	O
calcium-mediated	O
activation	O
of	O
c-fos	B-DNA
,	O
and	O
has	O
little	O
or	O
no	O
effect	O
when	O
combined	O
with	O
cAMP	O
.	O


IL-10	O
induces	O
the	O
tyrosine	O
phosphorylation	O
of	O
tyk2	B-protein
and	O
Jak1	B-protein
and	O
the	O
differential	O
assembly	O
of	O
STAT1	B-protein
alpha	I-protein
and	O
STAT3	B-protein
complexes	I-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
monocytes	B-cell_type
.	O


In	O
this	O
report	O
,	O
we	O
show	O
that	O
in	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
IL-10	B-protein
stimulates	O
tyrosine	O
phosphorylation	O
of	O
the	O
signal	B-protein
transducers	I-protein
and	O
activators	B-protein
of	I-protein
transcription	I-protein
,	O
STAT1	B-protein
alpha	I-protein
and	O
STAT3	B-protein
,	O
in	O
a	O
differential	O
manner	O
such	O
that	O
the	O
relative	O
formation	O
of	O
homo-	B-protein
and	I-protein
heterodimers	I-protein
varies	O
between	O
the	O
two	O
cell	O
types	O
.	O


Selective	O
modulation	O
of	O
immune	O
responsiveness	O
by	O
IL-10	B-protein
in	O
cells	O
such	O
as	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
may	O
result	O
in	O
part	O
from	O
the	O
differential	O
activation	O
of	O
STAT	B-protein
protein	I-protein
pairs	I-protein
.	O


All	O
the	O
markers	O
considered	O
were	O
sufficiently	O
sensitive	O
,	O
but	O
among	O
them	O
,	O
Platelet	B-protein
Factor	I-protein
IV	I-protein
was	O
the	O
most	O
reliable	O
to	O
the	O
hormonal	O
ovulatory	O
situation	O
.	O


They	O
also	O
display	O
constitutively	O
high	O
levels	O
of	O
p59fyn	B-protein
and	O
CD3	B-protein
zeta	I-protein
tyrosine	O
phosphorylation	O
.	O


Upon	O
mitogenic	O
stimulation	O
,	O
the	O
binding	O
activity	O
of	O
the	O
novel	O
NF-AT-binding	B-protein
factor	I-protein
is	O
rapidly	O
down-regulated	O
in	O
normal	O
T	B-cell_type
cells	I-cell_type
,	O
but	O
persists	O
at	O
high	O
levels	O
in	O
Ipr	B-cell_line
CD4-8-	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O


Cross-linking	O
of	O
CD30	B-protein
induces	O
HIV	O
expression	O
in	O
chronically	O
infected	O
T	B-cell_type
cells	I-cell_type
.	O


We	O
demonstrate	O
that	O
cross-linking	O
CD30	B-protein
with	O
an	O
anti-	O
CD30	B-protein
-specific	O
monoclonal	O
antibody	O
,	O
which	O
mimics	O
the	O
described	O
biological	O
activities	O
of	O
the	O
CD30	B-protein
ligand	I-protein
(	O
CD30L	B-protein
)	O
,	O
results	O
in	O
HIV	O
expression	O
.	O


Thus	O
,	O
CD30	B-protein
-CD30L	B-protein
interactions	O
mediate	O
the	O
induction	O
of	O
HIV	O
expression	O
by	O
a	O
kappa	O
B-dependent	O
pathway	O
that	O
is	O
independent	O
of	O
TNF	B-protein
.	O


Here	O
,	O
we	O
demonstrate	O
that	O
CIITA	B-DNA
is	O
an	O
MHC	B-DNA
class	I-DNA
II	I-DNA
gene-specific	I-DNA
transcription	I-DNA
activator	I-DNA
.	O


Monocyte	O
tethering	O
by	O
P-selectin	B-protein
regulates	O
monocyte	B-protein
chemotactic	I-protein
protein-1	I-protein
and	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
secretion	O
.	O


Adhesion	B-protein
molecules	I-protein
that	O
tether	O
circulating	B-cell_type
leukocytes	I-cell_type
to	O
endothelial	B-cell_type
cells	I-cell_type
may	O
also	O
transduce	O
or	O
modulate	O
outside-in	O
signals	O
for	O
cellular	O
activation	O
,	O
providing	O
an	O
initial	O
regulatory	O
point	O
in	O
the	O
inflammatory	O
response	O
.	O


Increased	O
cytokine	O
secretion	O
was	O
specifically	O
inhibited	O
by	O
G1	B-protein
,	O
an	O
anti-P-selectin	B-protein
mAb	I-protein
that	O
prevents	O
P-selectin	B-protein
from	O
binding	O
to	O
its	O
ligand	O
(	O
P-selectin	B-protein
glycoprotein	I-protein
ligand-1	I-protein
)	O
on	O
myeloid	B-cell_type
cells	I-cell_type
.	O


These	O
studies	O
have	O
defined	O
the	O
regulatory	O
roles	O
of	O
the	O
different	O
HS-40	B-DNA
motifs	I-DNA
.	O


Nitric	O
oxide-stimulated	O
guanine	O
nucleotide	O
exchange	O
on	O
p21ras	B-protein
.	O


These	O
studies	O
identify	O
p21ras	B-DNA
as	O
a	O
target	O
of	O
the	O
same	O
cell	O
.	O


Latent	B-protein
membrane	I-protein
protein-1	I-protein
induces	O
cyclin	B-protein
D2	I-protein
expression	O
,	O
pRb	B-protein
hyperphosphorylation	O
,	O
and	O
loss	O
of	O
TGF-beta	B-protein
1	I-protein
-mediated	O
growth	O
inhibition	O
in	O
EBV-positive	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O


Six	O
to	O
8	O
weeks	O
after	O
subtotal	O
thyroidectomy	O
,	O
the	O
number	O
of	O
patients	O
'	O
PBMC	B-cell_type
responding	O
to	O
any	O
peptide	O
and	O
the	O
average	O
number	O
of	O
recognized	O
peptides	O
decreased	O
.	O


Responses	O
of	O
PBMC	B-cell_type
from	O
patients	O
with	O
GD	O
,	O
maintained	O
euthyroid	O
on	O
ATD	O
,	O
were	O
lower	O
than	O
those	O
before	O
surgery	O
or	O
RAI	O
therapy	O
.	O


Molecular	O
events	O
that	O
underlie	O
the	O
well-defined	O
phenotypic	O
changes	O
of	O
the	O
differentiating	B-cell_type
thymocyte	I-cell_type
are	O
poorly	O
understood	O
.	O


The	O
PuF	B-DNA
site	I-DNA
on	O
the	O
silent	B-DNA
normal	I-DNA
c-myc	I-DNA
allele	I-DNA
was	O
unoccupied	O
.	O


Interaction	O
between	O
the	O
stage	B-DNA
selector	I-DNA
element	I-DNA
(	O
SSE	O
)	O
in	O
the	O
proximal	B-DNA
gamma-globin	I-DNA
promoter	I-DNA
and	O
hypersensitivity	B-DNA
site	I-DNA
2	I-DNA
in	O
the	O
locus	B-DNA
control	I-DNA
region	I-DNA
partly	O
mediates	O
the	O
competitive	O
silencing	O
of	O
the	O
beta-globin	B-DNA
promoter	I-DNA
in	O
the	O
fetal	O
developmental	O
stage	O
.	O


Mutation	O
of	O
a	O
20-base	O
pair	O
sequence	O
of	O
the	O
gamma-gene	B-DNA
5'-untranslated	I-DNA
region	I-DNA
(	O
UTR	B-DNA
)	O
led	O
to	O
derepression	O
of	O
beta-promoter	B-DNA
activity	O
.	O


Growth	O
regulation	O
and	O
cellular	O
changes	O
during	O
differentiation	O
of	O
human	B-cell_line
prostatic	I-cell_line
cancer	I-cell_line
LNCaP	I-cell_line
cells	I-cell_line
as	O
induced	O
by	O
T	O
lymphocyte-conditioned	O
medium	O
.	O


Activated	O
T	B-cell_type
cells	I-cell_type
were	O
demonstrated	O
to	O
be	O
important	O
in	O
providing	O
the	O
modulating	O
activity	O
.	O


To	O
clarify	O
properties	O
of	O
the	O
blast	B-cell_type
cells	I-cell_type
in	O
M7	O
and	O
TMD	O
cases	O
,	O
we	O
examined	O
erythroid	O
markers	O
expression	O
in	O
blasts	B-cell_type
from	O
six	O
cases	O
with	O
M7	O
and	O
seven	O
cases	O
with	O
TMD	O
in	O
this	O
study	O
.	O


We	O
have	O
previously	O
found	O
a	O
high	O
expression	O
of	O
human	B-RNA
Ah	I-RNA
receptor	I-RNA
(	I-RNA
TCDD	I-RNA
receptor	I-RNA
)	I-RNA
mRNA	I-RNA
in	O
peripheral	B-cell_type
blood	I-cell_type
cells	I-cell_type
of	O
individuals	O
.	O


Epstein-Barr	B-cell_type
virus	I-cell_type
(	I-cell_type
EBV	I-cell_type
)	I-cell_type
-infected	I-cell_type
cells	I-cell_type
may	O
sustain	O
three	O
distinct	O
forms	O
of	O
virus	O
latency	O
.	O


Detection	O
of	O
the	O
chromosome	B-RNA
16	I-RNA
CBF	I-RNA
beta-MYH11	I-RNA
fusion	I-RNA
transcript	I-RNA
in	O
myelomonocytic	O
leukemias	O
.	O


Fifty-three	O
cases	O
(	O
11	O
AML	O
M4Eo	O
;	O
1	O
AML	O
M4	O
with	O
atypical	B-cell_type
abnormal	I-cell_type
eosinophils	I-cell_type
(	O
AML	O
M4	O
``	O
Eo	O
''	O
)	O
;	O
29	O
AML	O
M4	O
;	O
8	O
AML	O
M5	O
;	O
3	O
CMML	O
;	O
and	O
1	O
AML	O
M2	O
with	O
eosinophilia	O
)	O
were	O
analyzed	O
.	O


Effects	O
of	O
glucocorticoids	O
on	O
transcription	O
factor	O
activation	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O


This	O
conclusion	O
is	O
discussed	O
in	O
relation	O
to	O
the	O
mechanism	O
of	O
corticoid	O
resistance	O
in	O
mouse	B-cell_line
and	I-cell_line
human	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
in	O
culture	O
.	O


